The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Manipulation of the Microbiota for Treatment of IBS and IBD—Challenges and Controversies
Open accessAbstract
There is compelling rationale for manipulating the microbiota to treat inflammatory bowel diseases (IBDs). Although studies of animal models of intestinal inflammation produced promising results, trials in humans have been disappointing. In contrast to IBD, the role of the microbiota in the development of irritable bowel syndrome (IBS) only recently has been considered, but early stage results have been encouraging. As pharmaceutical companies develop fewer truly novel agents for treatment of these disorders, consumers seek safer, long-term strategies to deal with chronic symptoms. We assess the rationale for modulating the microbiota for treatment of IBD and IBS, and discuss whether current concepts are simplistic and overstated or simply under-researched. Are claims exaggerated and expectations unrealistic? Difficulties with microbiota terminology and technologies, as well as differences among patients and the heterogeneity of these diseases, pose additional challenges in developing microbiota-based therapies for IBD and IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In some instances, changed microbiota may be an appropriate response to a change in the host, or may represent an epiphenomenon without pathophysiological implications [22] .”
From Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis (2014) · cites this paper as [22]
In the citing paper
“Despite the therapeutic potential of FMT for the treatment of PD, several limitations still exist and need to be addressed. Standard clinical protocols, delivery methods, periodicity, donor’s selection criteria, patient’s inclusion criteria, long-term benefits and potential risks remain an issue [463,467,481,482,483,484,485].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [483]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Consumption of fermented milk product with probiotic modulates brain activity
Tillisch, K., Labus, J., Kilpatrick, L., Jiang, Z., Stains, J., Ebrat, B., Guyonnet, D., Legrain–Raspaud, S., Trotin, B., Naliboff, B., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.043 · Cited by 1,192
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
O'Mahony, S. M., Marchesi, J. R., Scully, P., Codling, C., Ceolho, A.-M., Quigley, E. M. M., Cryan, J. F., & Dinan, T. G. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.026 · Cited by 1,069
Self-citationRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
The microbiome-gut-brain axis: from bowel to behavior
Cryan, J. F., & O’Mahony, S. M. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01664.x · Cited by 990
Bacteria, Colonic Fermentation, and Gastrointestinal Health
Macfarlane, G. T., & Macfarlane, S. (2012) · Journal of AOAC INTERNATIONAL · doi:10.5740/jaoacint.sge_macfarlane · Cited by 970
Cadwell, K., Patel, K., Maloney, N. S., Liu, T., Ng, A., Storer, C. E., Head, R. D., Xavier, R. J., Stappenbeck, T. S., & Virgin, H. W. (2010) · Cell · doi:10.1016/j.cell.2010.05.009 · Cited by 927
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Jeffery, I. B., O'Toole, P. W., Öhman, L., Claesson, M. J., Deane, J., Quigley, E. M. M., & Simrén, M. (2012) · Gut · doi:10.1136/gutjnl-2011-301501 · Cited by 835
Self-citationEradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Flagged first, then by citations
Cited by
Sorted by citations
Disease-Specific Alterations in the Enteric Virome in Inflammatory Bowel Disease
Norman, J. M., Handley, S. A., Baldridge, M. T., Droit, L., Liu, C. Y., Keller, B. C., Kambal, A., Monaco, C. L., Zhao, G., Fleshner, P., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.002 · Cited by 1,285
“One potential approach is the manipulation of enteric bacteria through probiotics and prebiotics, which have had limited success in humans thus far (Butterworth et al., 2008; Naidoo et al., 2011; Shanahan and Quigley, 2014).”
BackgroundParamsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276
Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M. D., Schemann, M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.14 · Cited by 1,102
Self-citationKynurenine pathway metabolism and the microbiota-gut-brain axis
Kennedy, P. J., Cryan, J. F., Dinan, T. G., & Clarke, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.002 · Cited by 724
“There is much interest in the minute regarding the possible wider application of faecal microbiota transplant beyond its use for the treatment of Clostridium difficile infection (Kelly et al., 2015a; Shanahan and Quigley, 2014).”
BackgroundGut microbiome and aging: physiological and mechanistic insights
Nagpal, R., Mainali, R., Ahmadi, S., Wang, S., Singh, R., Kavanagh, K., Kitzman, D. W., Kushugulova, A., Marotta, F., & Yadav, H. (2018) · Nutrition and Healthy Aging · doi:10.3233/nha-170030 · Cited by 670
Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis
Sivaprakasam, S., Prasad, P. D., & Singh, N. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.007 · Cited by 589
“…from diseased AC C EP TE D M AN U SC R IP T animals into germ-free or susceptible mice causes pathologies in recipients similar to those present in donors (Garrett, et al., 2007; Kostic, et al., 2013; Shanahan & Quigley, 2014; Turnbaugh, Backhed, Fulton, & Gordon, 2008; Vijay-Kumar, et al., 2010).”
The hologenome concept of evolution after 10 years
ROSENBERG, E. B., & Zilber‐Rosenberg, I. (2018) · Microbiome · doi:10.1186/s40168-018-0457-9 · Cited by 566
Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis
Tojo, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15163 · Cited by 533
Geirnaert, A., Calatayud, M., Grootaert, C., Laukens, D., Devriese, S., Smagghe, G. J., Vos, M. D., Boon, N., & de Wiele, T. V. (2017) · Scientific Reports · doi:10.1038/s41598-017-11734-8 · Cited by 452
Prebiotics: why definitions matter
Hutkins, R. W., Krumbeck, J. A., Bindels, L. B., Cani, P. D., Fahey, G. C., Jr., Goh, Y. J., Hamaker, B. R., Martens, E. C., Mills, D. A., Rastal, R. A., et al. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.09.001 · Cited by 460
“The necessity for open discussion about this topic is reflected in that the very basis for defining prebiotics has recently been challenged [45,46].”
BackgroundProbiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT
Barichella, M., Pacchetti, C., Bolliri, C., Cassani, E., Iorio, L., Pusani, C., Pinelli, G., Privitera, G., Cesari, I., Faierman, S. A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003127 · Cited by 390
“Our findings further support the theory that manipulation of the gut microbiota may be a therapeutic option for functional bowel disorder.(7) Nevertheless, the study did not enable us to establish which component of the experimental product had a major role.”
BackgroundResultModulating the microbiome to improve therapeutic response in cancer
McQuade, J. L., Daniel, C. R., Helmink, B. A., & Wargo, J. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30952-5 · Cited by 376
Prebiotics and Probiotics in Digestive Health
Quigley, E. M. M. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.09.028 · Cited by 404
Self-citationIrritable bowel syndrome: A microbiome-gut-brain axis disorder?
Kennedy, P. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14105 · Cited by 347
Dziarski, R., Park, S. Y., Kashyap, D. R., Dowd, S. E., & Gupta, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146162 · Cited by 342
Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives
Choi, H. H., & Cho, Y.-S. (2016) · Clinical Endoscopy · doi:10.5946/ce.2015.117 · Cited by 330
“The rationale for microbiota-directed interventions for treatment of IBS seems weaker than in IBD, but is emerging.(50) Although alterations in immunity, motility, and the brain-gut axis have been implicated in disease pathogenesis, the role of the intestinal microbiota are increasing, and numerous studies have demons…”
Microbiota regulation of the mammalian gut-brain axis
Burokas, A., Moloney, R. D., Dinan, T. G., & Cryan, J. F. (2015) · Advances in applied microbiology · doi:10.1016/bs.aambs.2015.02.001 · Cited by 300
Bloomfield, S. F., Rook, G. A. W., Scott, E. A., Shanahan, F., Stanwell-Smith, R., & Turner, P. (2016) · Perspectives in Public Health · doi:10.1177/1757913916650225 · Cited by 289
Self-citationThe microbiota in inflammatory bowel disease
Sheehan, D., Moran, C. P., & Shanahan, F. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1064-1 · Cited by 260
Self-citationPrebiotics, probiotics, synbiotics, and the immune system: experimental data and clinical evidence
Frei, R., Akdis, M., & O’Mahony, L. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000151 · Cited by 240
“cant component in several intestinal diseases, including inflammatory bowel disease, irritable bowel syndrome, and food allergies [1,2].”
BackgroundThe Potential Role of Gut Microbiota in Alzheimer’s Disease: From Diagnosis to Treatment
Varesi, A., Pierella, E., Romeo, M., Piccini, G. B., Alfano, C., Bjørklund, G., Oppong, A., Ricevuti, G., Esposito, C., Chirumbolo, S., et al. (2022) · Nutrients · doi:10.3390/nu14030668 · Cited by 225
The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease
Parekh, P. J., Balart, L. A., & Johnson, D. A. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.16 · Cited by 219
Probiotics in Inflammatory Bowel Disease
Abraham, B. P., & Quigley, E. M. M. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.08.003 · Cited by 217
Self-citationRecent Advances in Characterizing the Gastrointestinal Microbiome in Crohnʼs Disease
Wright, E. K., Kamm, M. A., Teo, S. M., Inouye, M., Wagner, J., & Kirkwood, C. D. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000382 · Cited by 219
“Probiotics has not been shown consistently to benefit Crohn’s disease.(34) Understanding in detail the compositional and functional changes in the GI microbiome and when these occur in”
BackgroundThe involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
Cammarota, G., Ianiro, G., Cianci, R., Bibbò, S., Gasbarrini, A., & Currò, D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.006 · Cited by 184
Putignani, L., CHIERICO, F. D., Vernocchi, P., Cicala, M., Cucchiara, S., & Dallapiccola, B. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000602 · Cited by 153
Probiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative Colitis
Mardini, H. E., & Grigorian, A. Y. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000084 · Cited by 140
Leaky gut – concept or clinical entity?
Quigley, E. M. M. (2016) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000243 · Cited by 139
“Furthermore, though supportive data are derived virtually exclusively from animal models, the ingestion of prebiotics and probiotics could, in contrast, enhance barrier integrity [22,23].”
BackgroundSelf-citationLong-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis
Ding, X. L., Li, Q., Li, P., Zhang, T., Cui, B., Ji, G., Lü, X., & Zhang, F. (2019) · Drug Safety · doi:10.1007/s40264-019-00809-2 · Cited by 139
Sivaprakasam, S., Gurav, A., Paschall, A. V., Coe, G. L., Chaudhary, K., Cai, Y., Kolhe, R. B., Martin, P. M., Browning, D. D., Huang, L., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.38 · Cited by 135
de León-Rodríguez, M. D. C. P., Guyot, J., & Laurent-Babot, C. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1506734 · Cited by 138
“Hence, food molecules and diverse microorganisms, including microbiota promote sustained activation of the mucosal immune system (Geremia et al. 2014; Shanahan and Quigley 2014; Vindigni et al. 2016).”
BackgroundGut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
“It also has the potential to manipulate gut microbiota by FMT in patients with IBD (126, 127).”
BackgroundConsensus report: faecal microbiota transfer – clinical applications and procedures
König, J., Siebenhaar, A., Högenauer, C., Arkkila, P. E. T., Nieuwdorp, M., Norén, T., Ponsioen, C. Y., Rosien, U., Rossen, N., Satokari, R. M., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13868 · Cited by 115
Methods and Reporting Studies Assessing Fecal Microbiota Transplantation
Bafeta, A., Yavchitz, A., Riveros, C., Batista, R., & Ravaud, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2810 · Cited by 111
Li, M., Liang, P., Li, Z., Wang, Y., Zhang, G., Gao, H., Shu, W., & Tang, L. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00692 · Cited by 109
“…of fecal suspension from healthy individuals to inflammatory bowel disease (IBD) (Bennet and Brinkman, 1989; Kunde et al., 2013; Kao et al., 2014) or irritable bowel syndrome (IBS) (Konig and Brummer, 2014; Shanahan and Quigley, 2014) patients resulted in clinical improvement and remission.”
BackgroundMujagic, Z., de Vos, P., Boekschoten, M. V., Govers, C., Pieters, H., de Wit, N. J. W., Bron, P. A., Masclee, A., & Troost, F. J. (2017) · Scientific Reports · doi:10.1038/srep40128 · Cited by 108
Geng, S., Cheng, S., Li, Y., Wen, Z., Ma, X., Jiang, X., Wang, Y., & Han, X. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy103 · Cited by 107
The Gut Microbiome in Health and Disease
Owyang, C., & Wu, G. D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.032 · Cited by 118
Metabolome of human gut microbiome is predictive of host dysbiosis
Larsen, P. E., & Dai, Y. D. (2015) · GigaScience · doi:10.1186/s13742-015-0084-3 · Cited by 98
“Already, microbiome transplants have proven a powerful tool for curing otherwise intractable diseases such as IBS [31–33] or antibiotic resistant * Correspondence: plarsen@anl.”
BackgroundKrych, Ł., Kot, W., Bendtsen, K. M., Hansen, A. K., Vogensen, F. K., & Nielsen, D. S. (2017) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2017.10.015 · Cited by 99
Microbiota-gut-brain research: A critical analysis
Hooks, K. B., Konsman, J. P., & O’Malley, M. A. (2018) · Behavioral and Brain Sciences · doi:10.1017/s0140525x18002133 · Cited by 109
Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome
Leshem, A., Horesh, N., & Elinav, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01341 · Cited by 96
“However, there is contradicting evidence as to the beneficial effect that probiotics have on human health, with large-scale, non-industry sponsored high-quality clinical trials still missing for the majority of claimed indications (38, 39).”
BackgroundMarlicz, W., Łoniewski, I., Grimes, D. S., & Quigley, E. M. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.07.015 · Cited by 91
Self-citationVaresi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
The Gut Microbiota in Inflammatory Bowel Disease
Sheehan, D., & Shanahan, F. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.09.011 · Cited by 88
Self-citationNusbaum, D. J., Sun, F., Ren, J., Zhu, Z., Ramsy, N., Pervolarakis, N., Kunde, S. S., England, W., Gao, B., Fiehn, O., et al. (2018) · FEMS Microbiology Ecology · doi:10.1093/femsec/fiy133 · Cited by 87
Tang, H.-Y., Jiang, A., Wang, X., Wang, H., Guan, Y., Li, F., & Shen, G.-M. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-2779 · Cited by 87
“A variety of meta-analyses reveal that probiotics, in general, benefit patients with IBS (101).”
Background(2015) · PubMed · Cited by 86
Microbiome in brain function and mental health
Kennedy, P. J., Murphy, A., Cryan, J. F., Ross, R. P., Dinan, T. G., & Stanton, C. (2016) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2016.05.001 · Cited by 81
“Bacterial colonization of the gut during early life influences normal development and maturation of the immune system, and across the lifespan, the gut microbiota regulate innate and adaptive immune responses (Shanahan & Quigley, 2014).”
BackgroundNew insights into irritable bowel syndrome: from pathophysiology to treatment
Hadjivasilis, A. (2019) · Annals of Gastroenterology · doi:10.20524/aog.2019.0428 · Cited by 76
“It is believed that they improve symptoms like abdominal pain and bloating by altering the intestinal microbiota, which may play an important role in the pathogenesis of IBS [116].”
BackgroundInflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering
Mishra, J., Stubbs, M., Kuang, L., Vara, N., Kumar, P., & Kumar, N. (2022) · Mediators of Inflammation · doi:10.1155/2022/9621668 · Cited by 75
“Probiotics also facilitate TLR-mediated T-helper 1 cell differentiation, thereby also augmenting antibody production, increasing phagocytic and natural killer cell activity, and upregulating anti-inflammatory cytokine interleukin- (IL-) 10 and transforming growth factor beta while concurrently downregulating proinflam…”
BackgroundIrritable bowel syndrome - from etiopathogenesis to therapy
Radovanović-Dinić, B., Tešić-Rajković, S., Grgov, S., Petrović, G., & Zivkovic, V. G. (2018) · Biomedical Papers · doi:10.5507/bp.2017.057 · Cited by 75
McQuade, J. L., Ologun, G. O., Arora, R., & Wargo, J. A. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00913-y · Cited by 63
Varesi, A., Deumer, U.-S., Ananth, S. V., & Ricevuti, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215077 · Cited by 66
Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases
Sundin, J., Öhman, L., & Simrén, M. (2017) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000470 · Cited by 61
“immune response to a normal microbiota or from a normal immune response to an abnormal microbiota (76).”
BackgroundThe role of the bacterial microbiome in the treatment of cancer
Yu, Z., Xie, R., You, R., Liu, Y., Chen, X.-Y., Chen, M., & Huang, P.-Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08664-0 · Cited by 57
Constipation and the Microbiome: Lumen Versus Mucosa!
Quigley, E. M. M., & Spiller, R. E. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.12.023 · Cited by 51
Self-citationThe microbiome of the oral mucosa in irritable bowel syndrome
Fourie, N. H., Wang, D., Abey, S. K., Sherwin, L. B., Joseph, P. V., Rahim-Williams, B., Ferguson, E. G., & Henderson, W. A. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1162363 · Cited by 53
“It is thought that the microbiome plays an integral role in IBS(2) and is an important target of intervention to relieve IBS symptoms.(3)”
BackgroundThe microbiome and childhood diseases: Focus on brain‐gut axis
O’Mahony, S. M., Stilling, R. M., Dinan, T. G., & Cryan, J. F. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21118 · Cited by 53
Walana, W., Ye, Y., Li, M., Wang, J., Wang, B., Cheng, J., Gordon, J., & Fang, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.008 · Cited by 49
Yu, C., Xiong, Y., Chen, D., Li, Y., Xu, B., Lin, Y., Tang, Z., Jiang, C., & Wang, L. (2017) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2017.21.1.1 · Cited by 48
“The differential diagnosis for distinguishing IBD and IBS based on clinical signs and symptoms are difficult [21-23].”
BackgroundLiu, Y., Heath, A. M., Galland, B. C., Rehrer, N. J., Drummond, L., Wu, X., Bell, T. J., Lawley, B., Sims, I. M., & Tannock, G. W. (2019) · Applied and Environmental Microbiology · doi:10.1128/aem.01905-19 · Cited by 48
Centanni, M., Hutchison, J. C., Carnachan, S., Daines, A. M., Kelly, W. J., Tannock, G. W., & Sims, I. M. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.11.017 · Cited by 47
Sanders, M. E. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000350 · Cited by 46
Sultan, S., & Malhotra, A. (2017) · Annals of Internal Medicine · doi:10.7326/aitc201706060 · Cited by 27
Verbeke, K., Boesmans, L., & Boets, E. (2014) · Proceedings of The Nutrition Society · doi:10.1017/s0029665114000639 · Cited by 46
Physiology of Electrolyte Transport in the Gut: Implications for Disease
Rao, M. C. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180011 · Cited by 54
Smolińska, S., Groeger, D., & O’Mahony, L. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.09.004 · Cited by 45
Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders
Camilleri, M., Bueno, L. P., Andresen, V., Ponti, F. D., Choi, M., & Lembo, A. J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.029 · Cited by 45
Chen, Q., Fan, Y., Zhang, B., Yan, C., Zhang, Q., Ke, Y., Chen, Z., Wang, L., Shi, H., Hu, Y., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04152-22 · Cited by 42
“tion of microbiota may be effective (3, 4).”
BackgroundProbiotics for inflammatory bowel disease: Is there sufficient evidence?
Ma, Y., Yang, D., Huang, J., Liu, K., Liu, H., Wu, H., & Bao, C. (2024) · Open Life Sciences · doi:10.1515/biol-2022-0821 · Cited by 42
“For probiotics with de fi nite e ff ects, it is recommended to investigate the bare minimum or precise probiotic required for speci fi c advantages, which would help normalize the treatment [122].”
BackgroundPrebiotics and Inflammatory Bowel Disease
Rasmussen, H. E., & Hamaker, B. R. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.08.004 · Cited by 38
Yue, B., Yu, Z., Lv, C., Geng, X., Wang, Z., & Dou, W. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i30.4378 · Cited by 38
Wirth, U., Jiang, T., Schardey, J., Kratz, K., Li, M., Schirren, M., Kühn, F., Bazhin, A. V., Werner, J., Guba, M. O., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054841 · Cited by 35
“Dysbiosis of gut b cteria is associated with various conditions, includi g obesity, diabe es, nonalcoholic fatty liver diseases, and autoimmune disorders [121,122], and even plays a significant role in I/R injury [123].”
BackgroundShabat, Y., Lichtenstein, Y., & Ilan, Y. (2020) · Inflammation · doi:10.1007/s10753-020-01348-0 · Cited by 33
Age-related diseases, therapies and gut microbiome: A new frontier for healthy aging
Barone, M., D’Amico, F., Rampelli, S., Brigidi, P., & Turroni, S. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111711 · Cited by 34
Bai, T., Xu, Z., Xia, P.-J., Feng, Y., Liu, B., Liu, H., Chen, Y., Yan, G., Lü, B., Yan, Z., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002147 · Cited by 34
Ghoshal, U. C., Gwee, K., Holtmann, G., Li, Y., Park, S. J., Marcellus Simadibrata, K., Sugano, K., Wu, K., Quigley, E. M. M., & Cohen, H. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13840 · Cited by 33
Self-citationModulating the Gut Microbiota of Humans by Dietary Intervention with Plant Glycans
Tannock, G. W. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.02757-20 · Cited by 33
Moran, C. P., Sheehan, D., & Shanahan, F. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000157 · Cited by 31
Self-citationCurciarello, R., Canziani, K. E., Salto, I., Romero, E. B., Rocca, A., Doldan, I., Peton, E., Brayer, S., Sambuelli, A. M., Goncalves, S. A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.658026 · Cited by 30
“These microorganisms in turnmay promote the release of pro-inflammatory factors such as TNF-α, which boost inflammation (Shawki and McCole, 2017).”
BackgroundStallmach, A., Quickert, S., Puta, C., & Reuken, P. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352744 · Cited by 30
Biomarker discovery in inflammatory bowel diseases using network-based feature selection
Abbas, M. M., Matta, J., Le, T., Bensmail, H., Obafemi-Ajayi, T., Honavar, V., & EL‐Manzalawy, Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225382 · Cited by 28
“Identification of microbial biomarkers is a promising direction, not only for predicting IBD onset but also for predicting IBD risk factors [11].”
BackgroundThe Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics
Zhao, Y., Zhu, S., Dong, Y., Xie, T., Chai, Z., Gao, X., Dai, Y., & Wang, X. (2024) · Biomolecules · doi:10.3390/biom14121643 · Cited by 32
“These strategies encompass antibiotics, prebiotics, probiotics, synbiotics, fecal microbiota transplantation (FMT), dietary modifications, and more [6].”
Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial
Ricci, C., Rizzello, F., Valerii, M. C., Spisni, E., Gionchetti, P., Turroni, S., Candela, M., D’Amico, F., Spigarelli, R., Bellocchio, I., et al. (2022) · Nutrients · doi:10.3390/nu14194208 · Cited by 28
“For instance, probiotics could modulate GM, and improve bowel movement frequency, bloating, pain, and flatulence, but it is not yet clear in which cases they may be useful and in what form, dose, combination, or strain [15,16].”
BackgroundIdrissi, D. A., Senhaji, N., Aouiss, A., Khalki, L., Tijani, Y., Zaïd, N., Marhoume, F. Z., Naya, A., Oudghiri, M., Kabine, M., et al. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01296-1 · Cited by 25
Nie, H., Wang, X., Luo, Y., Kong, F., Mu, G., & Wu, X. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c09675 · Cited by 26
Shanahan, F. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.101550 · Cited by 25
Self-citationClinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases
Muehler, A. R., Slizgi, J. R., Kohlhof, H., Groeppel, M., Peelen, E., & Vitt, D. (2020) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v11.i6.114 · Cited by 25
A phytopharmacological overview of medicinal plants used for prophylactic and treatment of colitis
Akkol, E. K., Karpuz, B., Sobarzo‐Sánchez, E., & Khan, H. Z. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111628 · Cited by 23
Eustis, S. J., McCall, M. W., Murphy, E. A., & Wirth, M. D. (2021) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2021.08.008 · Cited by 24
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 30
Diet and irritable bowel syndrome
Thomas, A. S., & Quigley, E. M. M. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000158 · Cited by 23
“Probiotics, Prebiotics and Synbiotics As the role of the microbiota in IBS has come to be explored and changes in microbial composition described, in IBS,([48]) enthusiasm for therapeutic interventions that could beneficially modulate the microbiota has increased.([49,50]) Among these, the food supplements probiotics,…”
Self-citationBarrett, K. E. (2016) · The Journal of Physiology · doi:10.1113/jp272227 · Cited by 23
Zhang, J., Chen, X., Mu, X., Hu, M., Wang, J., Huang, X., & Nie, S. (2021) · eFood · doi:10.53365/efood.k/147240 · Cited by 23
Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective
Giron, F., & Quigley, E. M. M. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18004 · Cited by 20
“component symptoms of IBS, such as bloating and abdominal pain.(89,92,93) Ultimately, recommendations for the use of probiotics in any gastrointestinal disorder must be based on evidence of the”
BackgroundSelf-citationClinical Trials of Probiotics in Patients With Irritable Bowel Syndrome: Some Points to Consider
Quigley, E. M. M. (2022) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm22012 · Cited by 17
“Furthermore, the antiinflammatory, anti-bacterial, anti-viral, gut barrier enhancing, enteric neuro-modulatory, and brain-gut axis modifying effects of specific probiotics have been demonstrated reproducibly in in vitro and animal models.(10,11) Many, if not all of these could be relevant to IBS.”
BackgroundSelf-citationCurrent Status and Prospects of Intestinal Microbiome Studies
Han, D. S. (2014) · Intestinal Research · doi:10.5217/ir.2014.12.3.178 · Cited by 17
“Changes in composition of microbiota and its metabolic functions are crucial for homeostasis of the immune system, and development of IBD.”
BackgroundInfluentialThe Gut-Brain Axis in Alzheimer’s Disease: Exploring Microbial Influences and Therapeutic Strategies
Mustafa, M. A., Vadia, N., Varma, P., Al‐Shaker, H., Mohanty, B., Dhyani, A., Kaur, I., Chauhan, A. S., & Garg, G. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05474-4 · Cited by 18
“Standardizing therapeutic protocols, determining optimal administration duration, assessing short-and long-term risks, and establishing appropriate inclusion criteria are crucial steps before FMT can be considered a viable treatment option for AD [329–331].”
Baker, C. C., Sessenwein, J. L., Wood, H. M., Yu, Y., Tsang, Q. K., Alward, T. A., Jiménez-Vargas, N. N., Omar, A. A., McDonell, A., Segal, J. P., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.03.006 · Cited by 16
Metadata
- Authors
- Shanahan, F., & Quigley, E. M. M.
- Affiliations
- National University of Ireland (IE)
- Houston Methodist (US)
- Corresponding author
- Shanahan, Fergus
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 146
- Issue
- 6
- Pages
- 1554-1563
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2172135635
- Cited by
- 172
- References
- 67
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 11 · 2021: 12 · 2020: 12 · 2019: 17 · 2018: 13 · 2017: 20 · 2016: 27 · 2015: 22 · 2014: 17
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut microbiota, microbiota-based therapy, irritable bowel syndrome, inflammatory bowel disease, microbiota modulation, intestinal inflammation, disease heterogeneity
- MeSH terms
- Animals, Biological Therapy, Feces, Humans, Intestines, Inflammatory Bowel Diseases, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Host-Pathogen Interactions, Prebiotics, Microbiota, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
